psychogenic

(redirected from Psychogenics)
Also found in: Dictionary, Thesaurus, Medical.

psychogenic

Psychol (esp of disorders or symptoms) of mental, rather than organic, origin

psychogenic

[¦sī·kō¦jen·ik]
(medicine)
Of psychic origin.
References in periodicals archive ?
The report provides brief overview of PsychoGenics, Inc.
In combination with our technologies for assessing behavior, PsychoGenics will be able to provide research support leading to the discovery of much needed new therapeutics.
Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for discontinued compounds such as Eltoprazine now in phase II trials for cognitive and motor disorders; as well as, early stage compounds with novel mechanisms of action.
25 May 2011 - German biotechnology company Evotec AG (FRA: EVT) said today that it has entered into a strategic alliance with US peer PsychoGenics Inc to provide integrated centarl nervous system (CNS) drug discovery solutions to pharmaceutical and biotechnology companies.
Dr Emer Leahy, President and CEO of PsychoGenics explained: "We are delighted to enter into this collaboration with Evotec, an innovative leader in drug discovery.
We are excited to enter into this alliance with KineMed which will allow Psychogenics to provide our clients and partners the ability to assess the effects of compounds on behavior and neurogenesis and correlate them with other neurochemical and molecular signals such as changes in transmitter and growth factor levels in the same animal," commented David Lowe, Ph.
Another innovative experimental platform now available through PsychoGenics is the use of microdialysis in a behaving animal, which allows direct correlation of transmitter changes with ongoing behavior.
Under the agreement, PsychoGenics will use its proprietary drug discovery technologies to evaluate a number of AstraZeneca drug candidates for their potential to treat psychiatric disorders.
Lowe has more than 25 years of experience in pharmaceutical drug discovery and product development and an established track record of generating diverse clinical candidates and he will lead the drug discovery and development efforts at PsychoGenics.
PsychoGenics Enters into Drug Discovery Agreement with Dainippon II-28
Recent Industry Activity II-25 Affymetrix Acquires USB Corp II-25 Roche Acquires Ventana Medical Systems II-25 Bruker BioSciences Acquires Bruker BioSpin Group II-25 Takeda Signs Agreement to Take Over Millennium II-25 Pfizer to Acquire Serenex II-26 Implant Sciences to Acquire Ion Metrics II-26 NascaCell and Archemix Expand Partnership for Aptamer-Based Drugs II-27 DiscoveRx and Cosmo Bio Sign Distribution Agreement II-27 Zydus Cadila Enters into Collaboration with Prolong Pharmaceuticals II-28 PsychoGenics Enters into Drug Discovery Agreement with Dainippon II-28 Zydus Cadila Collaborates with Karo Bio II-28 Nicholas Piramal's R&D Unit Extends Alliance with Eli Lilly II-29 Dr.